Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib with Niraparib +/- Atezolizumab in Ovarian Cancer
NCT03695380Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of cobimetinib in ovarian cancer (2 arms), sponsored by Roche. Primary endpoints: Number of patients reporting Adverse Events up to 48 months, Change from baseline in targeted clinical laboratory test results up to 48 months and 1 more. Started Jan 2019; status: completed.
02
Drugs
cobimetinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03695380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695380.